ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q2 FY26 results deck summary

NSE: SUDEEPPHRM · BSE: 544619

Results deck of 21 Dec 2025, summarised by AI from the filing.

Q2FY26 Total Income ₹172.8 cr (+15% YoY), PAT ₹46.8 cr (-4% YoY); management expects stronger H2 FY26 momentum.

Key takeaways

Guidance Management expects H2 FY26 to reflect stronger momentum than H1 FY26 as investments progress and customer activity builds.
Change NSS acquisition consolidated from 22nd May 2025, contributing to revenue and expanding global reach.
Driver Sustained demand and higher volumes across both business segments drove H1 FY26 performance.
Risk EBITDA margin declined to 38.0% in Q2FY26 from 43.4% in Q2FY25.

Original filing on BSE

Sudeep Pharma Limited Q1 FY27 results

As filed: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Q1 FY27: Earnings call (5 Aug 2026), Results deck (4 Aug 2026), Results deck (4 Aug 2026), Results deck (4 Aug 2026)
Q4 FY26: Earnings call (22 May 2026), Results deck (21 May 2026)
Q3 FY26: Earnings call (9 Feb 2026), Results deck (7 Feb 2026)
Q2 FY26: Earnings call (22 Dec 2025), Results deck (21 Dec 2025)

Figures from the company's filings with NSE and BSE. Not investment advice.